Loading news...
VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 32,826 shares, a drop of 62.6% from the February 12th total of 87,870 shares. Based on an average daily volume of 94,910 shares, the days-to-cover ratio
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions
VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 87,870 shares, a decrease of 88.7% from the January 29th total of 774,911 shares. Based on an average daily volume of 394,842 shares,
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim's commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines.
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation. Earnings and Valuation This table compares VivoSim
MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Earnings and Valuation This table compares MediciNova and
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD).
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development.